Home About Us Government Relations and Advocacy Media Contact Us Site Map Privacy Français  
Multiple Sclerosis Society of CanadaSociété canadienne de la sclérose en plaques
Multiple Sclerosis Living with Multiple Sclerosis Research Treatments Donate Now Get Involved Special Events

 


Get Involved
    share +

Government Relations and Advocacy
line

Photo: MS Society volunteers Brian Duck and Eugene Paquin meet with Ed Komarnicki, (centre) chair, House of Commons human resources committee.
MS Society volunteers Brian Duck and Eugene Paquin meet with Ed Komarnicki, (centre) chair, House of Commons human resources committee.

Until we end MS, people affected by the disease face many challenges. The Multiple Sclerosis Society of Canada works to ensure people with MS and their families have the opportunity to participate fully in all aspects of life. 

Across the country, the MS Society endeavours to change government policies, private industry practices and public attitudes in ways that will benefit people affected by MS. See our Policy Issues Statement.

Individual advocacy means working to assist yourself or another person to help obtain needed services and to maximize quality of life. For more information see Advocating for Yourself.


Survey on the Impact of MS Disease-Modifying Therapies

In late February, the Multiple Sclerosis Society of Canada will provide input on behalf of people with MS in regards to a review of the current and emerging disease-modifying therapies (DMT's) for MS taking place by the national agency that makes recommendations to provincial and territorial drug program decision makers.

The national agency - Canadian Agency for Drugs and Technologies in Health (CADTH) is currently undertaking a systematic review to compare the efficacy and safety of DMT's for patients with relapsing-remitting MS and will examine their cost-effectiveness.

The review will include DMT's that are currently available in Canada (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, and Tysabri) and newly emerging DMT's not yet approved in Canada (teriflunomide, dimethyl fumarate (BG-12), and alemtuzumab).

To ensure the views of Canadians affected by MS are truly represented, we are asking people with MS as well as caregivers to complete the following survey. Your answers will be incorporated into the submission to the national agency - CADTH.

Please complete the survey by Friday, March 1.


Join MS Society advocacy initiatives

Sign up to receive news, updates and opportunities for action. You can help shape policies and programs that impact people affected by MS.

 

Back to top

line
Charitable registration
10774 6174 RR0001
Multiple Sclerosis Society of Canada
Toll free to reach the nearest regional office: 1 800 268-7582

To locate the MS Society office near you, please select your region:

E-mail: info@mssociety.ca
(Please provide your town and province in your e-mail)

Multiple Sclerosis   Living with MS   Research   Treatments   Donate Now   Get Involved    Special Events

Home    About Us    Advocacy    Media    Contact Us    Site Map    Privacy    Français